ESMO AstraZeneca
Biotech

AstraZeneca drops MASH drug over disappointing data

AstraZeneca has ended work on one of its drugs for fatty liver disease after viewing disappointing data from a phase 2 study.
James Waldron Nov 6, 2025 5:21am
new york stock exchange

Inflammation biotech Evommune heads to NYSE with $150M IPO

Nov 6, 2025 7:00am
Syneos HealthOvarian Cancer Trials 16x9v2png

Protocol-Ready Doesn’t Mean Trial-Ready in Ovarian Cancer Clinical Trials

Nov 3, 2025 8:00am
Gavel with scales of justice in background

Judge denies Pfizer’s bid to block Novo’s offer for Metsera

Nov 5, 2025 5:23pm
How do you get pharmaceutical treatments where theyre needed most

How to get pharmaceutical treatments where they’re needed most.

Oct 6, 2025 8:00am
pipeline pipes RD research

Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus

Nov 6, 2025 1:26pm
More News
Fierce Healthcare

Government shutdown updates: Voters back extending ACA credits

Nov 6, 2025 1:00pm

Axsome adds AZ asset through Avenue subsidiary acquisition

Nov 6, 2025 10:50am

UroGen hands CTLA-4 drug back to Agenus after mulling ph. 1 data

Nov 6, 2025 10:00am

Illumina shares rise as China set to lift sequencer export ban

Nov 6, 2025 9:50am